The Proclaimsm (Proleukin® Observational Study to Evaluate Treatment Patterns and Clinical Response in Malignancy) Study: The Response Rates for High Dose Interleukin-2 (HD IL-2) Therapy

被引：0
|
作者：
Kaufman, Howard [1 ]
McDermott, David [2 ]
Morse, Michael [3 ]
Lowder, James [4 ]
Wong, Michael [5 ]
机构：
[1] Rush Univ, Chicago, IL 60612 USA
[2] Harvard Univ, Boston, MA 02115 USA
[3] Duke Univ, Durham, NC USA
[4] Prometheus Labs Inc, San Diego, CA USA
[5] Univ So Calif, Los Angeles, CA USA
来源：
JOURNAL OF IMMUNOTHERAPY | 2012年 / 35卷 / 09期
关键词：
Interleukin-2; Immunotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：749 / 750
页数：2
相关论文
共 50 条
  • [21] Efficacy and tolerability of high dose interleukin-2 (HD IL-2) after disease progression on targeted therapy (TT) for metastatic renal cell carcinoma (mRCC).
    Vu, Peter
    Mai, Hanh P.
    Adams, William
    Gonzalez, Beverly
    Kliethermes, Stephanie
    Clark, Joseph
    Henry, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] High-dose cyclophosphamide + carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma – a phase II study
    HC Toh
    SL McAfee
    R Sackstein
    P Multani
    BF Cox
    R Garcia-Carbonero
    C Colby
    TR Spitzer
    Bone Marrow Transplantation, 2000, 25 : 19 - 24
  • [23] Acute and Chronic Cardiopulmonary Effects of High Dose Interleukin-2 Therapy: An Observational Magnetic Resonance Imaging Study
    Lagan, Jakub
    Naish, Josephine H.
    Fortune, Christien
    Campbell, Christopher
    Chow, Shien
    Pillai, Manon
    Bradley, Joshua
    Francis, Lenin
    Clark, David
    Macnab, Anita
    Nucifora, Gaetano
    Dobson, Rebecca
    Schelbert, Erik B.
    Schmitt, Matthias
    Hawkins, Robert
    Miller, Christopher A.
    DIAGNOSTICS, 2022, 12 (06)
  • [24] High-dose cyclophosphamide plus carboplatin and interleukin-2 (IL-2) activated autologous stem cell transplantation followed by maintenance IL-2 therapy in metastatic breast carcinoma - a phase II study
    Toh, HC
    McAfee, SL
    Sackstein, R
    Multani, P
    Cox, BF
    Garcia-Carbonero, R
    Colby, C
    Spitzer, TR
    BONE MARROW TRANSPLANTATION, 2000, 25 (01) : 19 - 24
  • [25] Phase I trial of sequential decitabine plus high-dose interleukin-2 (HD IL-2) in patients with advanced melanoma.
    Gollob, J
    Thoreson, M
    Richmond, T
    Sciambi, C
    Bael, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 716S - 716S
  • [26] High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
    Davar, Diwakar
    Ding, Fei
    Saul, Melissa
    Sander, Cindy
    Tarhini, Ahmad A.
    Kirkwood, John M.
    Tawbi, Hussein A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [27] High-dose interleukin-2 (HD IL-2) for metastatic renal Cell carcinoma (mRCC): Contemporary utilization trends in the United States
    Allard, Christopher B.
    Gelpi-Hammerschmidt, Francisco
    Harshman, Lauren Christine
    Faiena, Izak
    Modi, Parth K.
    Chung, Benjamin I.
    Singer, Eric A.
    Chang, Steven L.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [28] Conditional survival (CS) of metastatic renal cell carcinoma (mRCC) patients treated with high-dose interleukin-2 (HD IL-2)
    Straubhar, Alli M.
    Stenehjem, David D.
    Parikh, Kinjal
    Merriman, Joseph
    Crispin, Hilda
    Sendlinathan, Arun
    Van Atta, Joan
    Batten, Julia A.
    Agarwal, Archana M.
    Tantravahi, Srinivas Kiran
    Samiowski, Wolfram E.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] STIMULATORY EFFECT OF THYROTROPIN (TSH) ON INTERLEUKIN-2 (IL-2) RELEASE FROM HUMAN PERIPHERAL-BLOOD LYMPHOCYTES - A DOSE-RESPONSE STUDY IN-VITRO
    KOMOROWSKI, J
    ZYLINSKA, K
    PAWLIKOWSKI, M
    STEPIEN, H
    HORMONE AND METABOLIC RESEARCH, 1993, 25 (11) : 598 - 599
  • [30] High-Dose Interleukin-2 Followed by Temozolomide Results in Response Rates of High Quality in Metastatic Melanoma
    Fateh, Salman
    Schell, Todd
    Gingrich, Rebecca
    Neves, Rogerio
    Drabick, Joseph
    JOURNAL OF IMMUNOTHERAPY, 2009, 32 (09) : 956 - 956
12345